Telegraft (@telegraft) profile picture

Official Newsletter of ISCT

Joined October 2020
Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)Photo by Telegraft (@telegraft)
🌍 #FORUM30 united 102 experts from 36 countries to advance MPHO safety&traceability! Hosted by @ICCBBA, @CNTrapianti, @CentroSangue & supported by @WHO, we explored future therapies & global regulatory harmony. A pivotal step for patient care worldwide! 🔗iccbba.isbt128.org/forum30
2
3
140
📢now #online in the latest isse of @ISCTglobal @telegraft a recap of @ISBT128's a brief recap of #FORUM30 where I presented Current challenges in cell and gene therapy: a joint view from the European Committee of the @ISCTglobal and the @TheEBMT 🔗isctglobal.org/telegrafthub/…
1
4
4
242
📢Now online! Human pluripotent stem cell-derived #retinal #pigment #epithelial cells #underthemicroscope by Dr. Laura Baqué Vidal @karolinskainst in the latest issue of @telegraft, the newsletter of the @ISCTglobal 🔗isctglobal.org/telegrafthub/…
1
2
1
151
Advances in stem-cell #therapy could hold the key to treating age-related #macular degeneration (AMD), a leading cause of blindness. Learn how retinal pigment epithelial (RPE) cells are being developed to stop #vision loss & offer new hope for millions worldwide! #AMD @telegraft
1
1
2
85
Replying to @xinoxan @telegraft
🤔What?🧐RPE are specialized cells on the back of the eye playing a fundamental role in the homeostasis of the #retina, e.g. visual cycle recycling, phagocytosis of old photoreceptors, secretion of growth factors, transport of nutrients and water, capture of not-transduced light
1
1
1
57
🤔Why?🧐Age-related #macular #degeneration (AMD) is a prevalent progressive #blindness disease in the elderly worldwide caused by degeneration of #RPEs. Cell replacement therapies could help in the #treatment of AMD. 📚doi.org/10.22608/apo.2017251
1
1
1
39
🤔Who?🧐Current strategies for treating AMD involve stem-cell-based RPE products develop in both academua and industry. 🔗doi.org/10.1080/078538906009…
1
1
1
33
🤔Where?🧐Leading countries developing clinical development of stem-cell-based RPE products include USA, Japan, Israel, UK, China and Republic of Korea. In some other countries, developments are still on the preclinical stage, including Sweden, Spain, India, Finland, Singapore.
1
1
1
27
🤔How?🧐#Stem cell-based #RPE products are #ATMP produced in compliance with pharmaceutical #GMP standards. Current #protocols yield >98% pure RPEs, although some developers use cell sorting procedures to enrich #RPEs from other #impurities.
1
1
1
15
🤔Did you know that…🧐#RPE have granules of #melanin, the same substance found in the skin that protects us from #UVlight and responsible of the color of our #hair? This makes it easier to work with these cells because they can be easily spotted for their dark brown color.
1
1
1
37
💡If you want to learn more on #pluripotent #stem cell-derived #epithelial #retinal #pigmental #cells, please read Dr. Laura Baqué Vidal's article in the latest issue of @Telegraft following this link: isctglobal.org/telegrafthub/…
1
1
48
In this #UTM @telegraft article, @CaicedoLab & @sebastianjpc1 present #mitochondria as a cell-free therapeutic option. 🔗isctglobal.org/telegrafthub/…
1
1
1
3
1,090
I am thrilled to have my video interview for the @ISCTglobal @telegraft Member Spotlight with Dr. Erja Kerkelä, Ph.D. out now! Enjoy this wonderful conversation with a fantastic researcher and champion of team science! youtu.be/k8XHLjlK_PY?si=tIS1… via @YouTube
1
2
8
488
My latest editorial on CAR-MSCs for the @ISCTglobal @telegraft - had a lot of fun writing this one! Check out the inspiration article from @kenderian_ss linked within. Enjoy! #celltherapy
Ever heard of CAR-MSCs? In the latest edition of the Telegraft, Editor @AshleyAKrull introduces – or re-introduces - the concept of CAR-MSCs and how the latest version of these cells from the lab of @kenderian_ss could impact the field. Read Now: buff.ly/3vSeg6Q
2
1
15
1,175